



# MERCK'S COMMITMENT TO ADDRESSING NON-COMMUNICABLE DISEASES (NCDs)

**NON-COMMUNICABLE DISEASES (NCDs) INCLUDING  
CANCER, DIABETES, AND CARDIOVASCULAR  
AND RESPIRATORY DISEASES HAVE LONG BEEN  
A BURDEN IN THE DEVELOPED WORLD.**

Today, NCDs pose an increasing burden on health and economic development in developing countries and emerging markets. Managing the global challenge of NCDs requires collaborative solutions, involving governments, civil society and private companies.

Merck (known as MSD outside of the United States and Canada) has a long history of leadership in discovering, developing and marketing medicines to prevent and treat NCDs. Through our internal activities and external partnerships, we are engaged in a wide range of activities aimed at addressing the burden of NCDs worldwide.

## COMMITMENT TO RESEARCH AND DEVELOPMENT

New medicines are essential tools in the effort to prevent and treat NCDs. Our current portfolio contains products that address key non-communicable diseases like cancer, diabetes, and cardiovascular and respiratory diseases. In February 2011 Merck CEO Ken Frazier committed to preserving a strong research and development program across all these areas.

More information: <http://www.merck.com/research/home.html>

## MEETING THE NEEDS OF EMERGING MARKETS

We recognize that patients in emerging markets have unique needs. For that reason, Merck is engaged in a number of collaborations as part of its commitment to improve health care by expanding the reach of our product offerings. Activities include developing innovative therapeutic combinations and formulations as well as expanded access mechanisms.

- Merck and **Sun Pharma** formed a joint venture to develop, manufacture and commercialize new combinations and formulations of innovative, branded generics in the emerging markets where we have strong customer reach and a compelling, innovative product portfolio.
- We established the **Oss Development Center** (Netherlands) and the **Mexico Pharmaceutical Development Labs** to develop novel, innovative formulations for existing Merck compounds.
- In Korea we expanded our collaboration with **Hanmi Pharmaceuticals** to expand the reach of a hypertension product in emerging markets.
- Merck and the **Simcere Pharmaceutical Group** formed a partnership to expand access to cardiovascular and metabolic pharmaceutical products in China.


These approaches will position us to expand access to Merck's innovations across a broader segment of the population.

More information: <http://www.merck.com/licensing/our-partnership/worldwide-alliances.html>

## PROMOTING HEALTHY LIFESTYLES

Merck recognizes that maintaining a healthy lifestyle is one of the best ways to prevent NCDs. We invest in programs that promote good nutrition globally and support our employees' workplace wellness at Merck.

- Merck invests significant resources in the developing and developed world to promote health education and good nutrition with partners such as **CARE/Save the Children**. In recent years, The Merck Company Foundation dedicated approximately \$5 million for programs to create sustainable solutions for reducing hunger for people of all ages around the world.
- Merck facilities throughout the world are improving workplace wellness. The majority are providing free screenings for important NCDs and taking steps to **reduce tobacco use**. Going forward, Merck will be implementing a global strategy to raise all offices up to industry-wide best practices in health and wellness.



## PROMOTING ACCESS

Merck seeks to commercialize our products in a way that develops our business and meets local needs in a responsible and efficient manner. Part of that approach involves pricing our products for NCDs through differential pricing frameworks, taking into consideration the level of economic development, channel and public health need.

- Within countries, we seek to identify **innovative strategies for differential pricing** or other approaches that allow for flexibility to better reach those most at-need. For example, in China, Merck took unilateral, voluntary action to lower the price for a well-known cholesterol drug when there was the opportunity to expand access to more patients.
- Through the **MerckHelps** program in the United States, we provide our medicines and adult vaccines for free to people who do not have prescription drug or health insurance coverage and who, without our assistance, cannot afford their Merck medicine and vaccines.



## BUILDING MULTI-STAKEHOLDER PARTNERSHIPS

We pride ourselves on the role we play in the communities where we live and work. Our approach is to listen to local needs and find ways to invest in areas relevant to our business and the skills of our people. We also are collaborating with community-based organizations, healthcare providers, academic institutions and other stakeholders in underserved communities to address the growing NCD epidemic.

- The **Merck Childhood Asthma Network** is working to promote an effective, real-world response to the challenge of childhood asthma in the United States.
- Through the **GoRed For Women Heart Health** campaign, of which Merck is a national sponsor in the United States, we're helping to raise awareness of cardiovascular disease.
- **SPARSH** is a patient support initiative for diabetes patients who are taking certain Merck medicines. The program was created in India in partnership with physicians who voiced the need for more robust patient support. Enrolled patients receive counseling on diabetes care, complications of diabetes, diet, and exercise through telephone calls.
- In Bhutan, Peru, Vietnam, India, and other countries Merck is helping to "prevent the preventable" by forming partnerships to screen girls for cervical cancer and ensure they have access to our **HPV vaccine**.

More information: <http://www.merck.com/responsibility/community/home.html>

## LEVERAGING TECHNOLOGY

Merck recognizes the increasing role of technology for informed decisions by patients, caregivers and health care providers. Health care technology will have an important role to play in helping patients maintain a healthy lifestyle and prevent NCDs.

- **MerckEngage Health Partnership Program** provides health care professionals with support materials and tools for their patients who have been prescribed certain Merck medications. The program is designed to support the health care professional-health care consumer relationship by providing tools and tips for healthier living and encouraging health care consumers to make healthier lifestyle choices between office visits. More information: <http://www.merckengage.com>
- **VREE** is Merck's mobile device interactive learning module to help patients understand and manage type 2 diabetes. Users receive mobile real-time reminders, a tracking system for blood glucose readings, and get medication, nutrition, and activity trackers as well as personal progress charts. More information: <http://www.vree-health.com>

# MERCK IS COMMITTED TO DISCOVERING NEW MEDICINES FOR NCDs AND TO WORKING WITH PARTNERS TO IMPROVE ACCESS TO THEM AROUND THE GLOBE.

Merck's overall commitment to access is found in our **Access to Health Statement of Guiding Principles at <http://www.merck.com/cr>**. We believe that we have a responsibility not only to discover innovative medicines, but also to innovate in how we improve them, how we use technology, and how we partner with the community to bring them to the people who need them. We call on all stakeholders: governments, industry, civil society, patients and caregivers – to engage in creative and collaborative partnerships to address NCDs.

Copyright © 2011 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. All rights reserved.

This statement includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such statements may include, but are not limited to, statements about the company's plans, objectives, expectations and intentions and other statements that are not historical facts. Such statements are based upon the current beliefs and expectations of Merck's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements.

The following factors, among others, could cause actual results to differ from those set forth in the forward-looking statements: the possibility that the expected synergies from the merger of Merck and Schering-Plough will not be realized, or will not be realized within the expected time period; the impact of pharmaceutical industry regulation and health care legislation; the risk that the businesses will not be integrated successfully; disruption from the merger making it more difficult to maintain business and operational relationships; Merck's ability to accurately predict future market conditions; dependence on the effectiveness of Merck's patents and other protections for innovative products; the risk of new and changing regulation and health policies in the U.S. and internationally and the exposure to litigation and/or regulatory actions.

Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in Merck's 2010 Annual Report on Form 10-K and the company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site ([www.sec.gov](http://www.sec.gov)).

